Pharmaceuticals, Biotechnology and Life Sciences
Researchers from the Dr. Piotr Witkowski Laboratory at the University of Chicago presented updated data on six patients with type…
OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…
Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND…
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing…
Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been…
Preliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genentech and conducted at…
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2…
— Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China – the facility is now expected…
Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well toleratedBOSTON and…
Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with…